What will the new price of Mounjaro be, and what drives it?

Why the new Mounjaro price is higher — and why dose matters so much

The jump that happened in autumn 2025 was significant. Lilly's UK list price for a 15mg pen moved from roughly £122 to roughly £330, more than doubling at the top of the dose ladder. Lower strengths moved by smaller margins, which is why the monthly cost a patient actually pays depends heavily on where they are in their titration schedule. Someone starting on 2.5mg pays far less than someone who has reached 12.5mg or 15mg after several months of treatment.

That staggered structure matters when you are weighing up cost over time. The question of whether Mounjaro prices will fall again is one a lot of people are asking, and the honest answer is that no confirmed reduction has been announced. Private providers set their own margins on top of the list price, so the range across the market is real.

One practical note: if you order by midday on a weekday, clinically approved treatment is dispatched the same day. That timing matters if you are running low before the weekend, something our prescribers flag regularly. If you are planning ahead, understanding what the new Mounjaro prices are expected to look like is part of mapping out the likely cost trajectory over months, which a proper consultation covers.

What headline prices often leave out

A quoted monthly price for Mounjaro is not always the total cost. Some providers charge separately for the initial consultation, the prescription, or each follow-up review. Delivery (which for a cold-chain medicine is not trivial) is sometimes added at checkout. Dose-titration support, the clinical assessment that decides whether you move from 5mg to 7.5mg, may or may not be included.

This is not a criticism of any particular service; it reflects how private healthcare pricing is structured. But it means that comparing two headline figures without knowing what each covers can lead to a misleading conclusion. A fuller breakdown of what private Mounjaro pricing typically includes helps you ask the right questions before committing.

NICE's appraisal of tirzepatide (TA1026, published December 2024) sets out the NHS eligibility criteria, which are strict and phased. Most people currently considering private treatment do so precisely because they fall outside those criteria or do not want to wait. That is a legitimate reason; just ensure the private route you choose includes genuine clinical oversight at every stage, not just at sign-up.

Where nume sits on the price spectrum, and why

We are not the cheapest option. That is a deliberate choice, not an oversight. One transparent price covers the consultation, the prescription, the treatment, tracked next-working-day delivery, and seven-day aftercare, nothing is added later. There are no subscriptions and no auto-renewals; every repeat order is assessed by a prescriber before it goes out.

A named clinician reads your consultation, our clinical team reviews each case personally. You can read about our approach on the about us page. Current treatment pricing is shown on the weight-loss treatments page; we do not print per-pen figures in editorial copy because the right dose for you is a clinical decision, not a menu choice.

For more on how different dose prices compare since the increase, our Mounjaro pricing overview and the updated price breakdown page cover the detail.

Why cheapest is the wrong question for a prescription medicine

A low price for Mounjaro from an unverified online seller is a red flag, not a bargain. The MHRA has warned explicitly about counterfeit weight-loss pens circulating online and via social media, fake pens that have in some cases contained insulin rather than tirzepatide. You can report any suspect seller via the MHRA's Yellow Card scheme. The only legal route to Mounjaro in the UK is a prescription issued following genuine clinical assessment, dispensed by a pharmacy you can verify on the GPhC register, nume's premises registration is 9012878.

Sellers offering these medicines without a prescription, at prices far below the market range, or with discount codes attached are not operating within UK law. The NHS tirzepatide guidance at NHS England's weight-management-injections page is clear that clinical wraparound support is part of safe treatment, not an optional extra.

The right metric is not which provider charges least. It is whether the supply chain is legitimate, the prescriber is qualified, and the clinical review is real. Those three things protect you in a way that saving £20 a month does not. Start your free consultation and see what a fully supervised, all-inclusive private route looks like.